Leerink Partners analyst Mani Foroohar reiterated a Hold rating on Alnylam Pharmaceuticals on Tuesday, setting a price target of $90, which is approximately 34.56% below the present share price of $137.53.
Foroohar expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$2.09 for the second quarter of 2021.
The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $171.67.
The analysts price targets range from a high of $235 to a low of $90.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $163.56 million and a net profit of -$194.22 million. The company's market cap is $16.14 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.3% and a 44.44% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.